Skip to content

Xeris Pharmaceuticals

US · XERS #2862 by market cap Listed 2018
16.97 +0.35 +2.11%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:57

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions increased by 8 in the most recent period (2026/Q3).
  • Total institutional ownership fell 1.0 percentage points.

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
64.16% -1.01pp
Institutions
290 +8
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund41.11%
Hedge Fund14.44%
Public Company4.69%
Individual/Insider3.38%
Insurance Company1.32%
Private Company0.89%
Government Pension Fund0.88%
Sovereign Wealth Fund0.46%
VC/PE Fund0.26%
Other32.56%

Top holders as of 2026-09-30

BlackRock 8.02% · 14.66M sh
D. E. Shaw & Co., L.P. 4.27% · 7.80M sh
Vanguard Capital Management, LLC 4.22% · 7.71M sh
State Street Global Advisors 3.05% · 5.57M sh
Geode Capital Management, LLC 2.50% · 4.57M sh
Teachers Insurance and Annuity Association-College Retirement Equities Fund 2.33% · 4.25M sh
Rosalind Advisors, Inc. 1.59% · 2.91M sh
Qube Research & Technologies Ltd 1.58% · 2.89M sh
Vanguard Portfolio Management, LLC 1.45% · 2.65M sh
Morgan Stanley 1.41% · 2.58M sh
Nuveen Asset Management LLC 1.32% · 2.41M sh
Wellington Management Group 1.30% · 2.37M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 17 buys · 33 sells

NameRoleStake
Kevin McCulloch President 0.87%
John Shannon Chairperson & CEO 0.85%
Steven Pieper Chief Financial Officer 0.50%
John Johnson Independent Non-Executive Director 0.37%
Beth Hecht Chief Legal Officer 0.32%
Garheng Albert Kong Independent Non-Executive Director 0.12%
Jeffrey Sherman Former Independent Director 0.10%
Marla Persky Lead Independent Director 0.07%
Barbar-Jean Bormann-Kennedy Independent Director 0.07%
Dawn Halkuff Independent Director 0.05%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-04 Kevin McCulloch President Automatic Disposition -25,000 $12.49
2026-11-01 Beth Hecht Chief Legal Officer Automatic Disposition -25,000 $10.23
2026-11-01 Kevin McCulloch President Automatic Disposition -15,000 $10.23
2026-11-01 Menassie Taddese Director Other Acquisition +22,365 --
2026-11-01 Menassie Taddese Director Other Derivative Disposition -31,499 $10.17
2026-11-01 Steven Pieper Chief Financial Officer Automatic Disposition -5,000 $10.23
2026-09-30 Beth Hecht Chief Legal Officer Automatic Disposition -16,666 $9.41
2026-09-30 Kevin McCulloch President Automatic Disposition -15,000 $9.41
2026-09-30 Steven Pieper Chief Financial Officer Automatic Disposition -5,000 $9.41
2026-09-27 Kevin McCulloch President Automatic Disposition -25,000 $10.00
2026-08-31 Beth Hecht Chief Legal Officer Automatic Disposition -16,666 $8.49
2026-08-31 Kevin McCulloch President Automatic Disposition -15,000 $8.49
2026-08-31 Steven Pieper Chief Financial Officer Automatic Disposition -5,000 $8.50
2026-08-11 Steven Pieper Chief Financial Officer Automatic Disposition -5,000 $8.50
2026-08-02 Beth Hecht Chief Legal Officer Automatic Disposition -16,666 $8.01
2026-08-02 Kevin McCulloch President Automatic Disposition -15,000 $8.02
2026-07-31 John Shannon Chairperson & CEO Sale to Issuer -36,645 $8.08
2026-07-31 Kevin McCulloch President Sale to Issuer -21,918 $8.08
2026-07-06 Steven Pieper Chief Financial Officer Automatic Disposition -45,000 $8.50–8.52
2026-07-06 Steven Pieper Chief Financial Officer Intent to Sell (Form 144) -27,600 $8.37

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:57:17 · For reference only, not investment advice and not tailored to your situation.

Xeris Pharmaceuticals discussion 0 comments

Add a comment